---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-385355"
form_type: "8-K"
ticker: "APMD"
cik: "0001745648"
company_name: "Apnimed, Inc."
filed_at: "2026-09-08T21:10:53+00:00"
generated_at: "2026-09-08T21:12:07.327432+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apnimed Q2 net income $125.9M on gains; FDA accepts AD109 NDA, PDUFA Feb 28 2027

## Summary
- Net income $125.9M vs net loss $69.5M year-ago; driven by $85.4M gain on equity-method investment sale and $57.1M deposit liability reversal.
- R&D expenses $9.9M, down 38% YoY ($16.0M); G&A $12.7M, up >100% from $5.4M on commercialization prep.
- Cash and equivalents $172.8M at June 30, 2026; upsized IPO raised $220.8M gross (13.8M shares at $16.00).
- FDA accepted NDA for AD109 (proposed name Oxnimbi) for obstructive sleep apnea; PDUFA target date Feb 28, 2027.
- Closed senior secured credit facility up to $150M with HealthCare Royalty Partners; monetized Shionogi-Apnimed interest for $100M upfront.

## SEC filing metadata
- accession: 0001193125-26-385355
- form_type: 8-K
- ticker: APMD
- cik: 0001745648
- company_name: Apnimed, Inc.
- filed_at: 2026-09-08T21:10:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/0001193125-26-385355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745648/000119312526385355/apmd-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-385355
- JSON: https://secwatch.observer/filing/0001193125-26-385355.json
- Plain text: https://secwatch.observer/filing/0001193125-26-385355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.